SCH 39304 in the treatment of acute or established murine pulmonary blastomycosis.
AUTOR(ES)
Brummer, E
RESUMO
SCH 39304 was tested for treatment of acute or established murine pulmonary blastomycosis and was compared with ketoconazole and fluconazole in a model of acute infection. Only SCH 39304 at 25 or 50 mg/kg of body weight per day produced 100% survival for 30 days after the 20-day treatment, although only 33% of the mice were cleared of infection. SCH 39304 at 2 mg/kg/day was similar to ketoconazole at 100 mg/kg/day and to fluconazole at 10 mg/kg/day. In a model of established blastomycosis, used to evaluate long-term treatment of very sick or moribund mice, SCH 39304 at 50 mg/kg/day protected against death with a 96% cumulative 8-week survival. SCH 39304 was clearly superior on a milligram-per-kilogram basis in acute blastomycosis, and long-term treatment of more severe blastomycosis was curative.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=245103Documentos Relacionados
- Treatment of murine pulmonary blastomycosis with SCH 39304, a new triazole antifungal agent.
- Treatment of murine coccidioidal meningitis with SCH39304.
- Treatment of murine pulmonary blastomycosis with SCH 51048, a broad-spectrum triazole antifungal agent.
- Fungal-strain-dependent alterations in the time course and mortality of chronic murine pulmonary blastomycosis.
- Efficacy of SCH39304 in murine cryptococcosis.
